FDA Sets Regulatory Review Period for SemprexSUPTM-D Capsules Patent Extension

Summary

The US Food and Drug Administration has determined the regulatory review period for the patent extension of SemprexSUPTM-D Capsules, a medication developed by a pharmaceutical company.